About
Who We Are
Leadership Team
Board of Directors
Clinical and Scientific Advisors
Contact
Science
Immune Continuum
CCR4 in Cancer
CCR4 in Inflammation
GCN2
Publications
Pipeline
Snapshot
FLX475
RPT193
GCN2i
HPK1
Discovery Programs
Investors & Media
Corporate Profile
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Email Alerts
Investor Contact
Investor FAQs
Careers
Culture
Benefits
Open Positions
PRESS RELEASES
Year
2021
2020
2019
2018
2017
Filter
June 18 | 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 15 | 2021
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
June 14 | 2021
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
June 14 | 2021
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
June 13 | 2021
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
May 20 | 2021
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 11 | 2021
RAPT Therapeutics Reports First Quarter 2021 Financial Results
March 22 | 2021
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
March 11 | 2021
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results
March 10 | 2021
RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR
